循环肿瘤DNA在肾细胞癌中的研究进展

Progress in research of circulating tumor DNA in renal cell carcinoma

随着二代测序技术的出现,肿瘤基因组学的研究不断推进,二代测序联合液体活检技术在实体肿瘤中的应用研究不断深入。目前研究表明循环肿瘤DNA检测可能成为肾癌早期诊断、精准用药及病程监测的生物标志物。本文将对近几年循环肿瘤DNA在肾癌中的研究进展进行综述,探讨循环肿瘤DNA对肾癌的诊断、精准用药以及疾病监测等方面的临床价值,为后续循环肿瘤DNA在肾癌中的研究提供方向。

With the development of next-generation sequencing, cancer genomics has made significant progress. The combination of liquid biopsy and next-generation sequencing is possessed of great potential throughout the clinical diagnosis and treatment of solid tumor. Recent studies have shown that the circulating tumor DNA might be a novel biomarker for patients with renal cell carcinoma, which can be used to guide patients’ early diagnosis, precision treatment and disease surveillance. This article reviews the research progress of circulating tumor DNA in renal cell carcinoma in recent years, to explore the clinical value of circulating tumor DNA in the diagnosis, precision treatment and disease monitoring of renal cell carcinoma, and to provide direction for the follow-up study of ctDNA in renal cell carcinoma.